Itonis Pharmaceuticals and Charles Hensley, Ph.D. to Begin Distributing Emesyl(TM) Anti-Nausea Homeopathic Product in Mexico
September 12 2013 - 8:30AM
Marketwired
Itonis, Inc.'s pharmaceutical division (PINKSHEETS: ITNS) and
Charles Hensley, Ph.D., the inventor of the Zicam® Cold Remedy, are
pleased to announce that Hensley Brothers Distribution, LLC ("HBD")
will distribute Emesyl(™), the Company's over-the-counter
homeopathic product for nausea relief, to Mexico through one of
HBD's distribution partners.
Dr. Hensley commented, "Entering the Mexican market will open up
the Central and South American markets, and we are pleased to have
Emesyl(™) enter the international market at such an early
stage."
Emesyl™ is the Company's anti-nausea relief product and is to be
manufactured by Oasis Health Products, Inc.
About Itonis Pharmaceuticals Itonis
Pharmaceuticals, a division of Itonis, Inc., is headed by Charles
Hensley, Ph.D. This division's mission is to create and market
over-the-counter and prescription homeopathic products that better
people's lives. Dr. Hensley is a pioneer in the development and
marketing of safe and effective therapeutic nutraceutical and
homeopathic preparations. He was a founder of the company that
launched the Zicam® Cold Remedy, making the product a household
name and forever changing the marketing and product placement
paradigm for homeopathic drugs in the United States. Dr. Hensley
and his team plan to use the same methodologies to revolutionize
the treatment of several other common ailments and other chronic
diseases.
About Itonis, Inc. Itonis, Inc. was
incorporated in the state of Nevada on July 5, 2005 under the name
of Kenshou, Inc., which later changed to Itonis, Inc. on December
2, 2005. For more information, please visit
www.itonisholdings.com.
Safe Harbor: Statements in this press
release may constitute forward-looking statements and are subject
to numerous risks and uncertainties, including the failure to
complete successfully the development of new or enhanced products,
the Company's future capital needs, the lack of market demand for
any new or enhanced products the Company may develop, any actions
by the Company's affiliates that may be adverse to the Company, the
success of competitive products, other economic factors affecting
the Company and its markets, seasonal changes, and other risks
detailed from time to time in the Company's filings with the U.S.
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Itonis, Inc. Email Contact (949) 200-8887
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Apr 2023 to Apr 2024